Inclisiran

From Wikipedia, the free encyclopedia
Inclisiran
Clinical data
Trade namesLeqvio
Other namesALN-PCSsc, ALN-60212
License data
Pregnancy
category
Routes of
administration		Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 1639324-58-5
DrugBank
UNII
KEGG
ChEBI
Chemical and physical data
FormulaC520H679F21N175O309P43S6
Molar mass16248.27 g·mol−1

Inclisiran, sold under the brand name Leqvio, is a medication for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk equivalents and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA that inhibits translation of the protein PCSK9.[5][6][7][2]

Inclisiran was approved for use in the European Union in December 2020.[4] In August 2021, it received NICE approval for use by the National Health Service in the UK.[8] In December 2021, it was approved for medical use in the United States.[3][9]

Medical uses[]

In the European Union, inclisiran is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in people unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies in people who are statin-intolerant, or for whom a statin is contraindicated.[4]

In the United States, it is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low- density lipoprotein cholesterol (LDL-C).[2][3]

History[]

In 2019, The Medicines Company announced positive results from pivotal phase III study (all primary and secondary endpoints were met with efficacy consistent with Phase I and II studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019, and in Europe in the first quarter of 2020.[10] Inclisiran is being developed by The Medicines Company, a subsidiary of Novartis, which licensed the rights to inclisiran from Alnylam Pharmaceuticals.[11][12]

The effectiveness of inclisiran was studied in three randomized, double-blind, placebo-controlled trials that enrolled 3,457 adults with HeFH or clinical ASCVD.[3] Enrolled participants were taking maximally tolerated statin therapy but required additional LDL-C lowering based on their risk for cardiovascular events.[3] In all three studies, the main effectiveness outcome measure was the percent change in LDL-C from the beginning of the trial to day 510 (month 17).[3] In each trial, participants received under-the-skin injections of either 284 mg inclisiran or a placebo on four separate days: day 1, day 90 (month 3), day 270 (month 9), and day 450 (month 15).[3]

Study 1 enrolled 1,561 adults with ASCVD.[3] At day 510, the inclisiran group had an average LDL-C decrease of 51% whereas the placebo group had an average LDL-C increase of 1%.[3] Study 2 enrolled 1,414 adults with ASCVD.[3] At day 510, the inclisiran group had an average LDL-C decrease of 46% whereas the placebo group had an average LDL-C increase of 4%.[3] Study 3 enrolled 482 adults with HeFH.[3] At day 510, the inclisiran group had an average LDL-C decrease of 40% whereas the placebo group had an average LDL-C increase of 8%.[3]

The effect of inclisiran on cardiovascular morbidity (suffering from a disease) and mortality (death) has not been determined.[3]

References[]

  1. ^ a b "Leqvio". Therapeutic Goods Administration (TGA). 22 September 2021. Retrieved 30 September 2021.
  2. ^ a b c "Leqvio- inclisiran injection, solution". DailyMed. Retrieved 27 December 2021.
  3. ^ a b c d e f g h i j k l m n "FDA approves add-on therapy to lower cholesterol among certain high-risk adults". U.S. Food and Drug Administration (FDA). 22 December 2021. Retrieved 24 December 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b c "Leqvio EPAR". European Medicines Agency. 13 October 2020. Retrieved 6 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. (January 2017). "A Highly Durable RNAi Therapeutic Inhibitor of PCSK9". The New England Journal of Medicine. 376 (1): 41–51. doi:10.1056/NEJMoa1609243. PMC 5778873. PMID 27959715.
  6. ^ Spreitzer H (11 September 2017). "Neue Wirkstoffe: Inclisiran". Österreichische Apotheker-Zeitung (in German) (19/2017).
  7. ^ "Proposed INN: List 114" (PDF). WHO Drug Information. WHO. 29 (4): 531f. 2015.
  8. ^ "Novartis signs deal with Britain's NHS for new cholesterol drug Leqvio". Reuters. 2021-09-01.
  9. ^ "FDA approves Novartis Leqvio (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year". Novartis (Press release). 22 December 2021. Retrieved 24 December 2021.
  10. ^ "The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran". The Medicines Company. Retrieved 29 August 2019.
  11. ^ Taylor NP (26 August 2019). "Medicines Company's PCSK9 drug hits phase 3 efficacy goals". FierceBiotech.
  12. ^ "Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran". Novartis (Press release). 6 January 2020. Retrieved 24 December 2021.

Further reading[]

External links[]

  • "Inclisiran". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03399370 for "Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10)" at ClinicalTrials.gov
  • Clinical trial number NCT03400800 for "Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)" at ClinicalTrials.gov
  • Clinical trial number NCT03397121 for "Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (ORION-9)" at ClinicalTrials.gov


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""